Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is caused by complement dysregulation and is generally diagnosed by exclusion from other disorders of thrombotic microangiopathy (TMA). Eculizumab, a terminal complement inhibitor, has been approved for aHUS treatment since 2013 in Japan. Recentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Hideo, Teranishi, Hirofumi, Shimono, Akihiko, Kato, Noritoshi, Maruyama, Shoichi, Matsumoto, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114489/
https://www.ncbi.nlm.nih.gov/pubmed/37072821
http://dx.doi.org/10.1186/s12959-023-00489-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114489/
https://www.ncbi.nlm.nih.gov/pubmed/37072821
http://dx.doi.org/10.1186/s12959-023-00489-0

Ejemplares similares